Delignit AG (DLX)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 2.500 |
|---|---|
| 52-week range | 1.930 – 2.900 |
| Return, 1 month / 3 months | +2.5% / +1.6% |
| Return, 1 year / 3 years | +16.2% / −29.7% |
| Trend | Uptrend |
| RSI (14) | 57 |
| Volatility (1 year) | 37.5% |
| Worst drawdown (1 year) | -15.3% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | 3.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Delignit AG is a German company based in Blomberg that develops and manufactures wood-based products for technical applications. Its main business is supplying high-tech panels and components to the automotive industry, where they are used in vehicle interiors, load floors and flooring systems. The company also serves rail vehicle manufacturers and other industrial customers with engineered wood solutions. Delignit works with customers on tailored components, combining wood materials with other materials to meet specific technical requirements.
The shares are listed on the XETRA Stock Exchange in Germany under the code DLX, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Delignit AG (DLX) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 2.500 on 23 October 2026.
Its price-based Market X-Ray is 52 out of 100 (a fair price profile), ranking 357 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 16.2% and over the last three months it rose 1.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 59 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 0.5% | ||
| From 52-week high | -10.7% | ||
| Momentum | 56 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 1.6% | ||
| 6-month return | -7.2% | ||
| 12-month return, skipping the last month | 13.4% | ||
| Stability (higher is calmer) | 68 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 37.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -15.3% | ||
| Liquidity | 16 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 40 · Weak | Dividend is small or irregular. | |
| Dividend yield | 3.2% | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.8% |
|---|---|
| 1 month | +2.5% |
| 3 months | +1.6% |
| 6 months | −7.2% |
| 1 year | +16.2% |
| 3 years | −29.7% |
| 5 years | −72.5% |
Signals
| 50-day / 200-day average | 2.465 / 2.489 |
|---|---|
| Golden / death cross (60 days) | Death, 27 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.070 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 19 Jun 2026 | EUR 0.0800 |
| 13 Jun 2025 | EUR 0.0500 |
| 7 Jun 2024 | EUR 0.0800 |
| 9 Aug 2023 | EUR 0.0500 |
| 23 Jun 2023 | EUR 0.0500 |
| 16 Jun 2021 | EUR 0.0275 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.